English | 简体中文 | 繁體中文 | 한국어
Share:
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

PRESS RELEASE

Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI®. IMFINZI® (durvalumab) is a human monoclonal antibody that blocks the immune checkpoint protein programmed death-ligand (PD-L1). Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in solid tumors. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. Up to 195 patients are planned to be enrolled in this multicenter, open-label study, which is planned to start during 2019.

"We are very pleased with NeoTX's progress in the ANYARA project. The collaboration with AstraZeneca validates the project and is an important step towards start of the clinical study" says Helén Tuvesson, CEO, Active Biotech AB.

See also www.neotx.com for NeoTX's communication related to this information.


ABOUT ANYARA

ANYARA (Naptumumab, Naptumomab estafenatox,) is a tumor targeting immunotherapy that enhances the ability of the immune system to recognize and kill the tumor. ANYARA induces the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells. Preclinical data demonstrate that ANYARA has synergistic effect with checkpoint inhibitors in various tumor models.

Active Biotech has an agreement with NeoTX Therapeutics Ltd since October 2016 for the global development and commercialization of ANYARA for the treatment of cancer.

About NeoTX
NeoTX Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies.

Lund February 11 2019


Helèn Tuvesson
President & CEO

For further information, please contact:
Helén Tuvesson, CEO
Tel +46 46 19 21 56

Hans Kolam, CFO
Tel +46 46 19 20 44

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 14.00p.m. CET on February 11, 2019.




This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details  
Apr 19, 2019 21:00 ET
SDLP - Seadrill Partners LLC receives early termination notice for the West Capricorn contract  
Apr 18, 2019 13:29 ET
CF&B Communication : Copenhagen May 16, 2019 - 30 listed companies, 40 institutional investors in One-to-One  
Apr 18, 2019 10:21 ET
Invitation to UPM's webcast and press conference on first quarter 2019 results  
Apr 18, 2019 09:00 ET
Nokia provides recast comparative segment results and additional financial disclosures for 2018 reflecting the new financial reporting structure  
Apr 18, 2019 08:01 ET
Lubrizol to Feature New Bio TPU Grades for 3D Printing and Molded Parts at Plastteknik Fair 2019  
Apr 17, 2019 22:59 ET
JCPenney Names New Principal Accounting Officer and Announces Key Strategic Executive Appointments  
Apr 17, 2019 19:59 ET
Lubrizol is Ready for ILSAC GF-6 - Announcing Lubrizol® PV1510 Additive Technology for the GF-6 Specification  
Apr 16, 2019 03:59 ET
JANET BAWCOM JOINS INGREDION AS GENERAL COUNSEL AND CORPORATE SECRETARY  
Apr 15, 2019 22:29 ET
Lubrizol Showcases Renewable-Sourced Estane® 3D ECO TPU for 3D Printing at RAPID + TCT 2019  
Apr 12, 2019 20:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: